中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (10): 2198-2199.doi: 10.4103/1673-5374.369110

• 观点:退行性病与再生 • 上一篇    下一篇

发现一种双作用小分子,可改善阿尔茨海默病小鼠的神经病理学特征

  

  • 出版日期:2023-10-15 发布日期:2023-03-28

Multi-faceted small molecule for Alzheimer’s disease

Min Hee Park, Hee Kyung Jin*, Jae-sung Bae*#br#   

  1. KNU Alzheimer’s Disease Research Institute, Department of Physiology, School of Medicine, Kyungpook National University, Daegu, South Korea (Park MH, Bae JS)
    KNU Alzheimer’s Disease Research Institute, Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea (Jin HK)
  • Online:2023-10-15 Published:2023-03-28
  • Contact: Jae-sung Bae, DVM, PhD, jsbae@knu.ac.kr; Hee Kyung Jin, DVM, PhD, hkjin@knu.ac.kr.
  • Supported by:
    This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) 2018M3C7A1056513, 2020R1A2C3006734 (to HKJ), 2020R1A2C3006875 (to JSB). This research was also supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare and MSIT, Republic of Korea (HU20C0345) (to JSB).  

摘要: https://orcid.org/0000-0002-8270-0072 (Jae-sung Bae) 
https://orcid.org/0000-0001-6403-008X (Hee Kyung Jin) 

Abstract: The main pathologies of Alzheimer’s disease (AD) are the accumulation of amyloid-β (Aβ) and tau tangles, and these two fundamental pathologies accompany the various neuropathological features, such as neuroinflammation, loss of synapse and neurogenesis, disruption of the blood-brain barrier (BBB), autophagy dysfunction, and cognitive impairment (Lee et al., 2014; Sweeney et al., 2018; Kashyap et al., 2019; Park et al., 2022). AD is thus considered a multi-factorial disease in which each of these complex neuropathological features somehow interrelates, eventually leading to neuronal and functional loss in the nervous system. Although researchers have focused on Aβ and tau tangles for the development of therapeutics for AD, the clinical efficacy of drugs targeting these major pathologies remains controversial. Moreover, other currently available drugs that are not effective in treating AD solely provide symptomatic relief to patients with AD. For this reason, researchers are on the onlook for new strategies to treat AD and emphasize the importance of multi-target directed drugs.